A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

• by Jin-Hui Chen, Tsen-Fang Tsai

• May 2, 2026

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy

• by Zeno Fratton, Stefano Bighetti, Luca Bettolini, Marina Venturini, Mariateresa Rossi, Andrea Carugno, Nicola Zerbinati, Giuseppe Stinco, Enzo Errichetti

• June 28, 2026

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

• by Andrea Surnit

• July 6, 2026

• 3 min

Development of Arthritis in a Large Real-World Cohort of Patients With Pediatric Onset Psoriasis

• by Malak Al-Gawahiri, Elke M. G. J. de Jong, Ellen J. H. Schatorjé, Esther P. A. H. Hoppenreijs, Juul M. P. A. van den Reek, Marieke M.B. Seyger

• April 25, 2026